Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer’s disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by ¹HNMR, ¹³CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ₄₂ and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 µM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC₅₀) value of 0.91 ± 0.05 µM and half-maximal effective concentration (EC₅₀) value of 3.83 ± 0.51 µM for the inhibition of AChE and cellular tau oligomerization, respectively. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs.

多靶点配体的开发已证明作为阿尔茨海默病 (AD) 的潜在疗法具有显着的效率。在此，我们报道了一系列新的脱氧血管紧张素类似物作为乙酰胆碱酯酶 (AChE) 和 tau 聚集的双重抑制剂，可作为 AD 的多靶点配体。所有多靶点配体11(aj)和15(ag ) 均经过¹ HNMR、¹³ CNMR 和质谱法设计、合成和验证。筛选了所有合成的化合物11(aj)和15(ag ) 抑制 AChE、BACE1、淀粉样蛋白纤维化、α-syn 聚集和 tau 聚集的能力。所有筛选的化合物都对 BACE-1、A β具有弱抑制作用₄₂和 α-syn 聚合。然而，在 AChE 抑制筛选试验和细胞 tau 聚集筛选中，有几种化合物被鉴定为潜在的命中物。在所有化合物中，11f在单剂量筛选 (10 µM) 时显着抑制 AChE 活性和细胞 tau 寡聚化。此外，11f的半数抑制浓度 (IC ₅₀ ) 值分别为 0.91 ± 0.05 µM 和半数最大有效浓度 (EC ₅₀ ) 值 3.83 ± 0.51 µM，分别用于抑制 AChE 和细胞 tau 寡聚化。此外，神经保护作用11F与tau蛋白孵育表达SH-SY5Y细胞，测定β低聚物。这些发现强调了11f作为多功能配体的潜力，可用于开发有前景的抗 AD 药物。